My name is Robyn and I am also from milwaukee. What doctors do you see for your adhesion problems. I have adhesions from the three mymectomies that I have had for removal of fibroids. I have been trying to get pregnant for over a year now with no success. I will be undergoing ivf soon. Has anyone on this bored not gotten there AF from adhesions? I have not gotten my period for over 2 months now.
Robyn
Adhesions Society wrote:
> ADHESIONS Digest 390
>
> Topics covered in this issue include:
>
> 1) ADHESION RECURRENCE
> by JJHEINZ@UWM.EDU (JIM)
> 2) Re: ADHESION RECURRENCE
> by "Karla Nygren" <ifirgit@up.net>
> 3) Post-op adhesions often lead to more surgery.
> by "Helen Dynda" <olddad66@runestone.net>
> 4) Sepramesh - a Genzyme surgical product - receives FDA Clearance...March 22, 2000
> by "Helen Dynda" <olddad66@runestone.net>
> 5) Sepramesh.......Here is the website!
> by "Helen Dynda" <olddad66@runestone.net>
> 6) ADCON-P...offers HOPE in the future for gynecological pelvic surgery.
> by "Helen Dynda" <olddad66@runestone.net>
> 7) ADEPT...a new post operative reduction solution is in clinical studies in the USA.
> by "Helen Dynda" <olddad66@runestone.net>
> 8) ADCON-P.....additional website information
> by olddad66@runestone.net (Helen Dynda)
> 9) pain clinic wants pain block
> by kaysan@iwon.com (kay)
> 10) About Adhesions...for clinicians - but helps an adhesion sufferer understand....
> by "Helen Dynda" <olddad66@runestone.net>
> 11) About Adhesions...for Patients
> by "Helen Dynda" <olddad66@runestone.net>
>
> ----------------------------------------------------------------------
>
> ----------------------------------------------------------------------
> Date: Fri, 14 Apr 2000 22:16:03 -0500 (CDT)
> ----------------------------------------------------------------------
> From: JJHEINZ@UWM.EDU (JIM)
> To: adhesions@adhesions.org
> Subject: ADHESION RECURRENCE
> Message-ID: <200004150316.WAA21575@forum.obgyn.net>
>
> I had a small bowel resection for intestinal obstruction due to crohn's
> disease in 1997.
> In Mar 1999 I developed obstructive symptoms and had another resection.
> Extensive adhesions were detected and repaired at that time, although
> they had not caused any symptoms.
>
> In Sep 99 I developed obstructive symptoms. A barium xray showed a
> definite narrowing of the intestine at one point. However, xrays in Feb
> 2000 showed no narrowing. Last week I had the most violent obstructive
> attack I've ever had. My doctors suspect adhesions.
>
> My question is: do obstructions due to adhesions in effect come and go,
> or are they continuous? What do they look like on a xray?
>
> --
> Jim from Milwaukee
>
> ------------------------------
>
> ------------------------------
> Date: Fri, 14 Apr 2000 23:43:34 -0500
> ------------------------------
> From: "Karla Nygren" <ifirgit@up.net>
> To: <adhesions@obgyn.net>
> Subject: Re: ADHESION RECURRENCE
> Message-ID: <001001bfa695$2952e6a0$32fd10d0@pioneer.net>
> MIME-Version: 1.0
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: 7bit
>
> Hi Jim,
>
> I have had a few bowel resections due to obstruction. I don't believe they
> were total obstructions. Since then I have had many occasions where I felt
> there was an obstruction and went for weeks without a bowel movement, but
> was told that there was no obstruction, but a narrowing. I believe that in
> the case of adhesions eventually the obstruction will break free. This is
> my opinion....and I am sure there are others who have had total
> obstructions.
>
> Jim, I am from Wisconsin as well and have sought all my care in Milwaukee.
> If you don't mind would you please share where you received your care?
>
> Karla N.
>
>> ----- Original Message -----
> From: JIM <JJHEINZ@UWM.EDU>
> To: Multiple recipients of list ADHESIONS <adhesions@forum.obgyn.net>
> Sent: Friday, April 14, 2000 10:16 PM
> Subject: ADHESION RECURRENCE
>
> > I had a small bowel resection for intestinal obstruction due to crohn's
> > disease in 1997.
> > In Mar 1999 I developed obstructive symptoms and had another resection.
> > Extensive adhesions were detected and repaired at that time, although
> > they had not caused any symptoms.
> >
> > In Sep 99 I developed obstructive symptoms. A barium xray showed a
> > definite narrowing of the intestine at one point. However, xrays in Feb
> > 2000 showed no narrowing. Last week I had the most violent obstructive
> > attack I've ever had. My doctors suspect adhesions.
> >
> > My question is: do obstructions due to adhesions in effect come and go,
> > or are they continuous? What do they look like on a xray?
> >
> > --
> > Jim from Milwaukee
> >
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 14:07:46 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: Post-op adhesions often lead to more surgery.
> Message-ID: <000801bfa70d$e685b900$4c18ddcc@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_000_0005_01BFA6E3.F97EFFA0"
>
> ------=_NextPart_000_0005_01BFA6E3.F97EFFA0
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> Tina Shelby posted this message on April 30, 1999. Unfortunately it was > very difficult to read because of the way it was received on the April > 1999 Adhesions Message Board. Tina said that she "found it to be very > interesting." And I agree that there is much food for thought in the > following article:
>
> ``````````````````````````
>
> At Fri, 30 Apr 1999, Tina Shelby wrote:
>
> I found this article on Excite's newspage. I found it to be very > interesting - Tina Shelby
>
> "Post-op adhesions often lead to more surgery" - (Last updated 1:13 PM > ET April 30)
>
> NEW YORK, Apr 30 - (Reuters Health)
>
> Adhesions -- fibrous bands or "internal scars" common after abdominal > surgery -- are a frequent cause of hospital readmissions and subsequent > surgeries, according to a report.
>
> More care should be taken to prevent the formation of adhesions, UK > researchers suggest, Their report is published in the May 1st issue of > The Lancet.
>
> A survey of Scottish patients revealed that "at least one in > 18...readmissions (for operative and non-operative treatment)...were > directly related to adhesions," according to a team led by Dr. Harold > Ellis of The Guy's, King's College and St. Thomas's School of Biomedical > Sciences in London, UK.
>
> Adhesions are fibrous bands of scar tissue that form within days, > months, or even years of abdominal surgery. Studies show that almost > 95% of patients, who have undergone such surgery, develop adhesions. > While most adhesions cause patients no harm, a minority can lead to > complications, such as intestinal blockage or, in women, infertility. > Repeat surgery is the only method of adhesion removal.
>
> Ellis and colleagues used government databases to track the 10-year > medical histories of 29,790 Scottish citizens admitted for pelvic or > abdominal surgeries in 1986.
>
> They report that 34.6% of these patients were later readmitted to the > hospital "for a disorder directly or possibly related to adhesions, or > for...surgery that could be potentially complicated by adhesions." > Close to 6% of all readmissions were directly linked to complications > caused by adhesions.
>
> Scar tissue formation following intestinal surgeries " had the highest > percentage of readmissions directly related to adhesions (7.3%)," > according to the authors. Nearly 3% of women undergoing gynecological > surgeries needed subsequent surgery because of adhesions.
>
> Because surgical removal of these scar tissues may not prevent > reoccurrence of an adhesion at the same site, experts believe prevention > is the best method of reducing the number of these postoperative > complications.
>
> In a commentary, Dr. Lena Holmdahl,of Goteborg University in Sweden > notes that medicated or procedural therapies performed during surgery > can reduce the likelihood of the formation of these "surgical > footprints." She is optimistic that the UK study " will stimulate the > industry, administrators, and surgeons alike to acknowledge the size of > the problem posed by adhesions and to act."
>
> SOURCE: The Lancet 1999; 354: 1476-1480, 1456-1457.
>
> ------=_NextPart_000_0005_01BFA6E3.F97EFFA0
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV><FONT face=Arial size=2>Tina Shelby posted this message on > April 30,
> 1999. Unfortunately it was very difficult to read because of the > way it
> was received on the April 1999 Adhesions Message Board. Tina > said
> that she "found it to be very interesting." And I agree that there > is much
> food for thought in the following article:</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>``````````````````````````</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>At Fri, 30 Apr 1999, Tina Shelby
> wrote:</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>I found this article on Excite's > newspage. I
> found it to be very interesting - Tina Shelby</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>"Post-op adhesions often lead to more > surgery" -
> (Last updated 1:13 PM ET April 30)</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>NEW YORK, Apr 30 - (Reuters > Health)</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Adhesions -- fibrous bands or "internal > scars"
> common after abdominal surgery -- are a frequent cause of hospital > readmissions
> and subsequent surgeries, according to a report.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>More care should be taken to prevent > the formation
> of adhesions, UK researchers suggest, Their report is published in the > May 1st
> issue of The Lancet.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>A survey of Scottish patients revealed > that "at
> least one in 18...readmissions (for operative and non-operative
> treatment)...were directly related to adhesions," according to a team > led by Dr.
> Harold Ellis of The Guy's, King's College and St. Thomas's School of > Biomedical
> Sciences in London, UK.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Adhesions are fibrous bands of scar > tissue that
> form within days, months, or even years of abdominal surgery. > Studies show
> that almost 95% of patients, who have undergone such surgery, develop
> adhesions. While most adhesions cause patients no harm, a minority > can
> lead to complications, such as intestinal blockage or, in women,
> infertility. Repeat surgery is the only method of adhesion
> removal.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Ellis and colleagues used government > databases to
> track the 10-year medical histories of 29,790 Scottish citizens admitted > for
> pelvic or abdominal surgeries in 1986.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>They report that 34.6% of these > patients were later
> readmitted to the hospital "for a disorder directly or possibly related > to
> adhesions, or for...surgery that could be potentially complicated by
> adhesions." Close to 6% of all readmissions were directly linked > to
> complications caused by adhesions.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Scar tissue formation following > intestinal
> surgeries " had the highest percentage of readmissions directly related > to
> adhesions (7.3%)," according to the authors. Nearly 3% of > women
> undergoing gynecological surgeries needed subsequent surgery because of
> adhesions.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Because surgical removal of these scar > tissues may
> not prevent reoccurrence of an adhesion at the same site, experts > believe
> prevention is the best method of reducing the number of these > postoperative
> complications.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>In a commentary, Dr. Lena > Holmdahl,of
> Goteborg University in Sweden notes that medicated or procedural > therapies
> performed during surgery can reduce the likelihood of the formation of > these
> "surgical footprints." She is optimistic that the UK study " will
> stimulate the industry, administrators, and surgeons alike to > acknowledge the
> size of the problem posed by adhesions and to act."</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>SOURCE: The Lancet 1999; > 354:
> 1476-1480, 1456-1457.</FONT></DIV></BODY></HTML>
>
> ------=_NextPart_000_0005_01BFA6E3.F97EFFA0--
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 17:11:00 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: Sepramesh - a Genzyme surgical product - receives FDA Clearance...March 22, 2000
> Message-ID: <000c01bfa727$7e254c80$4c18ddcc@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/mixed;
> boundary="----=_NextPart_000_0008_01BFA6FD.92E3C2C0"
>
> ------=_NextPart_000_0008_01BFA6FD.92E3C2C0
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_001_0009_01BFA6FD.92EB63E0"
>
> ------=_NextPart_001_0009_01BFA6FD.92EB63E0
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> I am not sure if this article will appear on the Message Board; so if > it doesn't, I will search for the URL so that you may read the article.
>
> [] Genzyme Surgical Products today announced that it has received > 510(k) clearance from the FDA to market Sepramesh Biosurgical Composite > for use in hernia repair procedures.
>
> ------=_NextPart_001_0009_01BFA6FD.92EB63E0
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV style="FONT: 10pt arial"></DIV>
> <DIV><FONT face=Arial size=2>I am not sure if this article will > appear on the
> Message Board; so if it doesn't, I will search for the URL so that > you may
> read the article. </FONT></DIV>
> <DIV><FONT face=Arial size=2></FONT> </DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>[] Genzyme Surgical Products > today announced
> that it has received 510(k) clearance from the FDA to market Sepramesh
> Biosurgical Composite for use in hernia repair procedures.</FONT></DIV>
> <DIV> </DIV>
> <DIV> </DIV></BODY></HTML>
>
> ------=_NextPart_001_0009_01BFA6FD.92EB63E0--
>
> ------=_NextPart_000_0008_01BFA6FD.92E3C2C0
> Content-Type: application/octet-stream;
> name="International Adhesions Society (3).url"
> Content-Transfer-Encoding: 7bit
> Content-Disposition: attachment;
> filename="International Adhesions Society (3).url"
>
> [DEFAULT]
> BASEURL=http://www.adhesions.org/forums/index.htm
>
> [DOC#4#5]
> BASEURL=http://www.adhesions.org/left.htm
> ORIGURL=../left.htm
>
> [DOC#4#6]
> BASEURL=http://www.genzyme.com/ir/gzsp/press/20000322.html
> ORIGURL=message.htm
>
> [InternetShortcut]
> URL=http://www.adhesions.org/forums/index.htm
> Modified�D5C1E425A7BF0106
>
> ------=_NextPart_000_0008_01BFA6FD.92E3C2C0--
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 17:25:44 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: Sepramesh.......Here is the website!
> Message-ID: <000b01bfa729$8bf43b80$4c18ddcc@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_000_0008_01BFA6FF.A1948640"
>
> ------=_NextPart_000_0008_01BFA6FF.A1948640
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> Here is the website for:
>
> [] Genzyme Surgical Products Receives FDA Clearance for > Sepramesh...March 22, 2000
>
> http://www.genzyme.com/ir/gzsp/press/20000322.html
>
> ------=_NextPart_000_0008_01BFA6FF.A1948640
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV style="FONT: 10pt arial"></DIV>
> <DIV><FONT face=Arial size=2>Here is the website > for:</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>[] Genzyme Surgical Products > Receives FDA
> Clearance for Sepramesh...March 22, 2000</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2><A
> href="http://www.genzyme.com/ir/gzsp/press/20000322.html">http://www.ge> nzyme.com/ir/gzsp/press/20000322.html</A></FONT></DIV></BODY></HTML>
>
> ------=_NextPart_000_0008_01BFA6FF.A1948640--
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 17:39:41 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: ADCON-P...offers HOPE in the future for gynecological pelvic surgery.
> Message-ID: <002f01bfa72b$7ebfe200$4c18ddcc@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/mixed;
> boundary="----=_NextPart_000_002B_01BFA701.94602CC0"
>
> ------=_NextPart_000_002B_01BFA701.94602CC0
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_001_002C_01BFA701.94602CC0"
>
> ------=_NextPart_001_002C_01BFA701.94602CC0
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> Gliatech's ADCON-P is a proprietary, resorbable, carbohydrate polymer > liquid designed to inhibit postsurgical scarring and adhesions following > gynecological pelvic surgery.
>
> [] Gliatech Announces Acceptance of Premarket Approval Modular Review > Process for ADCON - P........April 6, 2000
>
> http://www.gliatech.com/news/newsread.cfm?ID=192
>
> ------=_NextPart_001_002C_01BFA701.94602CC0
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV><FONT face=Arial size=2>Gliatech's ADCON-P is a proprietary, > resorbable,
> carbohydrate polymer liquid designed to inhibit postsurgical scarring > and
> adhesions following gynecological pelvic surgery.</FONT></DIV>
> <DIV><FONT face=Arial size=2></FONT> </DIV>
> <DIV><FONT face=Arial size=2>[] Gliatech Announces Acceptance > of Premarket
> Approval Modular Review Process for ADCON - P........April 6,
> 2000</FONT></DIV><BR> <A
> href="http://www.gliatech.com/news/newsread.cfm?ID=192">http://www.gl> iatech.com/news/newsread.cfm?ID2</A></BODY></HTML>
>
> ------=_NextPart_001_002C_01BFA701.94602CC0--
>
> ------=_NextPart_000_002B_01BFA701.94602CC0
> Content-Type: application/octet-stream;
> name="Gliatech Corporate Information.url"
> Content-Transfer-Encoding: 7bit
> Content-Disposition: attachment;
> filename="Gliatech Corporate Information.url"
>
> [DEFAULT]
> BASEURL=http://www.gliatech.com/news/newsread.cfm?ID=192
>
> [InternetShortcut]
> URL=http://www.gliatech.com/news/newsread.cfm?ID=192
> Modified D406382AA7BF0143
>
> ------=_NextPart_000_002B_01BFA701.94602CC0--
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 18:00:51 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: ADEPT...a new post operative reduction solution is in clinical studies in the USA.
> Message-ID: <004801bfa72e$73b15940$4c18ddcc@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/mixed;
> boundary="----=_NextPart_000_0044_01BFA704.8926EA80"
>
> ------=_NextPart_000_0044_01BFA704.8926EA80
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_001_0045_01BFA704.8926EA80"
>
> ------=_NextPart_001_0045_01BFA704.8926EA80
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> Click: "press releases"...then scroll down to and click "the title of > this article"...finally, scroll down to the information for this > article.
>
> [] ML progresses towards US approval of ADEPT. Interim results of USA > trials filed with FDA...November 18, 1999.
>
> http://www.mllabs.co.uk/pages/pr.htm
>
> ------=_NextPart_001_0045_01BFA704.8926EA80
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV><FONT face=Arial size=2>Click: "press releases"...then > scroll down to
> and click "the title of this article"...finally, scroll down to the > information
> for this article.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>[] ML progresses towards US > approval of
> ADEPT. Interim results of USA trials filed with FDA...November 18, >
> 1999</FONT><FONT face=Arial size=2>. </FONT></DIV>
> <DIV> </DIV>
> <DIV><A
> href="http://www.mllabs.co.uk/pages/pr.htm">http://www.mllabs.co.uk/pag> es/pr.htm</DIV></A></BODY></HTML>
>
> ------=_NextPart_001_0045_01BFA704.8926EA80--
>
> ------=_NextPart_000_0044_01BFA704.8926EA80
> Content-Type: application/octet-stream;
> name="ML LABORATORIES.url"
> Content-Transfer-Encoding: 7bit
> Content-Disposition: attachment;
> filename="ML LABORATORIES.url"
>
> [DEFAULT]
> BASEURL=http://www.mllabs.co.uk/pages/pr.htm
>
> [DOC#5#6#7]
> BASEURL=http://www.mllabs.co.uk/pages/prmenu.htm
> ORIGURL=prmenu.htm
>
> [DOC#5#6#8]
> BASEURL=http://fusion.trinetimb.net/ml_labs/press/list.cfm
> ORIGURL=http://fusion.trinetimb.net/ml_labs/press/list.cfm
>
> [DOC#5#9]
> BASEURL=http://www.mllabs.co.uk/pages/rgmenu.htm
> ORIGURL=rgmenu.htm
>
> [InternetShortcut]
> URL=http://www.mllabs.co.uk/pages/pr.htm
> ModifiedÀ0D149D2CA7BF0111
>
> ------=_NextPart_000_0044_01BFA704.8926EA80--
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 18:09:07 -0500 (CDT)
> ------------------------------
> From: olddad66@runestone.net (Helen Dynda)
> To: adhesions@obgyn.net
> Subject: ADCON-P.....additional website information
> Message-ID: <200004152309.SAA17017@forum.obgyn.net>
>
> The entire website does not function as it should. So, when you are at
> the following website (below), click: "Press Releases" and you will be
> able to read the following article.
>
> ````````````````````
>
> At Sat, 15 Apr 2000, Helen Dynda wrote:
>
> Gliatech's ADCON-P is a proprietary, resorbable, carbohydrate polymer
> liquid designed to inhibit postsurgical scarring and adhesions following
> gynecological pelvic surgery.
>
> [] Gliatech Announces Acceptance of Premarket Approval Modular Review
> Process for ADCON - P........April 6, 2000
>
> http://www.gliatech.com/news/newsread.cfm?ID2
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 19:54:58 -0500 (CDT)
> ------------------------------
> From: kaysan@iwon.com (kay)
> To: adhesions@obgyn.net
> Subject: pain clinic wants pain block
> Message-ID: <200004160054.TAA29599@forum.obgyn.net>
>
> Has anyone who has gone to a pain clinic had a pain block done wich
> would block the pain to the internal organs?? My doctor wants to try
> this on me. I am a little apprehensive about the procedure. I guess he
> does not want to continue giving Lorcett for the pain and wants to try
> this. But in the mean time...I suffer. My quality of life is greatly
> diminished and I am so frustrated. If any of you have heard of this or
> have had it done...please respond. Thanks
>
> --
> Kay
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 20:38:37 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: About Adhesions...for clinicians - but helps an adhesion sufferer understand....
> Message-ID: <002701bfa744$86fb63e0$cb1593ce@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_000_0024_01BFA71A.94298300"
>
> ------=_NextPart_000_0024_01BFA71A.94298300
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> Since there has been no activity at the forum today, I decided to copy > "About Adhesions" from the Clinician's segment of the Genzyme website. > This entire article can be found by clicking the website at the very end > of this article. My purpose in copying it word-for-word was to inform > you that there is an article on the Internet, which you can take with > you to give to your doctors/surgeons...an article which makes it clear > that adhesions can cause chronic pain!
>
> *+*+*+*+*+*+*+*+*+*+*
>
> ABOUT ADHESIONS
>
> Adhesion formation occurs during the natural and normal tissue repair > process, when tissue surfaces that usually are separated adhere to each > other. The body's cavities and internal organs are covered by > membranes. In the abdomen and pelvis, this membrane is known as the > peritoneum (The serous sac that lines the abdominal cavity and covers > most of the viscera therein). The peritoneum protects and lubricates > the external surface of the organs they cover. When the peritoneum is > damaged, for example during surgery, a protein called fibrin (a protein > derived from fibrinogen) can accumulate on the injured surface, making > it sticky. This sticky surface can then adhere to other areas of > peritoneum. These sticky bands are called adhesions. Under normal > circumstances, fibrin present at the site of mesothelial (An epithelial > tissue that lines body cavities and covers visceral organs; also known > as the serosa.) damage is broken down by plasmin (An enzyme that > converts fibrin to soluble products.). Plasmin is derived from > plasminogen, a protein found in the blood. Tissue plasminogen activator > (A chemical activator released from mesothelial cells) converts > plasminogen into plasmin. Through a process called fibrinolysis, the > plasmin then breaks down the fibrin into a substance that is absorbed by > the peritoneum.
>
> [ There is an illustration here which displays the EVOLUTION OF A > FIBRINOUS ADHESION. This complex illustration is perhaps meant for > medical professionals; but some of you will be able to understand the > process which is being displayed. ]
>
> Permanent adhesions form when fibrinolysis does not occur following the > formation of the fibrin matrix. In the setting of ischemia (reduced > blood flow) or inflammation, plasminogen is not activated and plasmin > does not form. Consequently, the fibrin cannot be broken down and a > permanent adhesion forms.
>
> Adhesions can cause tissues or organs to adhere to each other, often > limiting the mobility of organs and inducing pain. Adhesions are > associated with chronic abdominal and pelvic pain, intestinal > obstruction, female infertility and can make future operations much more > difficult.
>
> The incidence of adhesions is overwhelming. ADHESIONS DEVELOP IN UP TO > 93 PERCENT OF PATIENTS FOLLOWING ABDOMINAL AND PELVIC SURGERY.
>
> Postsurgical adhesions cause up to 74 percent of bowel obstructions. > Over 20 percent of adhesive intestinal obstructions occur within one > month of surgery, and up to 40 percent will occur within one year.
>
> The consequences of adhesions are substantial. Postsurgical adhesions > are responsible for 20 to 50 percent of chronic pelvic pain cases. > Adhesions also are a leading cause of female fertility causing 15 to 20 > percent of cases. Quality of life is greatly impaired.
>
> Quite often a patient will undergo surgery to lyse adhesions, only to > have them reform. Once a patient has undergone a colorectal procedure, > the incidence of reoperation within two years is high--up to 20 percent > of those patients will have a subsequent colorectal procedure in that > time. Between 2.3 percent and 5 percent of patients will undergo > adhesiolysis for bowel obstruction within two years of colorectal > surgery.
>
> Reoperations are often complicated by adhesions. Consequently, surgeons > must spend a considerable amount of time from ten minutes to hours > dividing adhesions before the current procedure can begin. This > prolongs the patient's recovery and increases the surgical risk and > cost.
>
> The economic impact associated with treating postsurgical adhesions is a > tremendous burden on health care. Hospitalizations due to adhesiolysis > contributed $1.3 billion to health care expenditures in 1994. During > that same year, hospitalizations due to adhesiolysis totaled 846,415 > days. When adhesiolysis was the primary procedure, the average length > of stay in the hospital was 9.7 days, at an average cost of over > $13,000.00.
>
> http://www.genzyme.com/prodserv/surgical_products/seprafilm/clinician/wel> come.htm
>
> ------=_NextPart_000_0024_01BFA71A.94298300
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV><FONT face=Arial size=2>Since there has been no activity at the > forum
> today, I decided to copy "About Adhesions" from the Clinician's segment > of the
> Genzyme website. This entire article can be found by clicking the > website
> at the very end of this article. My purpose in copying it > word-for-word
> was to inform you that there is an article on the Internet, which you > can take
> with you to give to your doctors/surgeons...an article which makes > it clear
> that adhesions can cause chronic pain!</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>*+*+*+*+*+*+*+*+*+*+*</FONT></DIV>
> <DIV><FONT face=Arial size=2></FONT> </DIV>
> <DIV><FONT face=Arial size=2>ABOUT ADHESIONS</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Adhesion formation occurs during the > natural and
> normal tissue repair process, when tissue surfaces that usually are > separated
> adhere to each other. The body's cavities and internal organs are > covered
> by membranes. In the abdomen and pelvis, this membrane is known as > the
> peritoneum (The serous sac that lines the abdominal cavity and covers > most of
> the viscera therein). The peritoneum protects and lubricates the > external
> surface of the organs they cover. When the peritoneum is damaged, > for
> example during surgery, a protein called fibrin (a protein derived from
> fibrinogen) can accumulate on the injured surface, making it > sticky. This
> sticky surface can then adhere to other areas of peritoneum. These > sticky
> bands are called adhesions. Under normal circumstances, fibrin > present at
> the site of mesothelial (An epithelial tissue that lines body cavities > and
> covers visceral organs; also known as the serosa.) damage is > broken down
> by plasmin (An enzyme that converts fibrin to soluble products.). > Plasmin
> is derived from plasminogen, a protein found in the blood. Tissue
> plasminogen activator (A chemical activator released from mesothelial > cells)
> converts plasminogen into plasmin. Through a process called > fibrinolysis,
> the plasmin then breaks down the fibrin into a substance that is > absorbed by the
> peritoneum.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>[ There is an illustration
> here which displays the EVOLUTION OF A FIBRINOUS > ADHESION. This
> complex illustration is perhaps meant for medical professionals; > but some
> of you will be able to understand the process which is being
> displayed. ]</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Permanent adhesions form when > fibrinolysis does not
> occur following the formation of the fibrin matrix. In the setting > of
> ischemia (reduced blood flow) or inflammation, plasminogen is not > activated and
> plasmin does not form. Consequently, the fibrin cannot be broken > down and
> a permanent adhesion forms.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Adhesions can cause tissues or organs > to adhere to
> each other, often limiting the mobility of organs and inducing > pain.
> Adhesions are associated with chronic abdominal and pelvic pain,
> intestinal obstruction, female infertility and can make future > operations much
> more difficult.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>The incidence of adhesions is > overwhelming.
> ADHESIONS DEVELOP IN UP TO 93 PERCENT OF PATIENTS FOLLOWING ABDOMINAL > AND PELVIC
> SURGERY.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Postsurgical adhesions cause up to 74 > percent of
> bowel obstructions. Over 20 percent of adhesive intestinal > obstructions
> occur within one month of surgery, and up to 40 percent will occur > within one
> year.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>The consequences of adhesions are
> substantial. Postsurgical adhesions are responsible for 20 to 50 > percent
> of chronic pelvic pain cases. Adhesions also are a leading cause > of female
> fertility causing 15 to 20 percent of cases. Quality of life is > greatly
> impaired.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Quite often a patient will undergo > surgery to lyse
> adhesions, only to have them reform. Once a patient has undergone > a
> colorectal procedure, the incidence of reoperation within two years is > high--up
> to 20 percent of those patients will have a subsequent colorectal > procedure in
> that time. Between 2.3 percent and 5 percent of patients will > undergo
> adhesiolysis for bowel obstruction within two years of colorectal
> surgery.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Reoperations are often complicated by
> adhesions. Consequently, surgeons must spend a considerable amount > of time
> from ten minutes to hours dividing adhesions before the current > procedure can
> begin. This prolongs the patient's recovery and increases the > surgical
> risk and cost.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>The economic impact associated with > treating
> postsurgical adhesions is a tremendous burden on health care.
> Hospitalizations due to adhesiolysis contributed $1.3 billion to health > care
> expenditures in 1994. During that same year, hospitalizations due > to
> adhesiolysis totaled 846,415 days. When adhesiolysis was the > primary
> procedure, the average length of stay in the hospital was 9.7 days, at > an
> average cost of over $13,000.00.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2><A
> href="http://www.genzyme.com/prodserv/surgical_products/seprafilm/clini> cian/welcome.htm">http://www.genzyme.com/prodserv/surgical_products/sepra> film/clinician/welcome.htm</A></FONT></DIV></BODY></HTML>
>
> ------=_NextPart_000_0024_01BFA71A.94298300--
>
> ------------------------------
>
> ------------------------------
> Date: Sat, 15 Apr 2000 21:22:30 -0500
> ------------------------------
> From: "Helen Dynda" <olddad66@runestone.net>
> To: <adhesions@obgyn.net>
> Subject: About Adhesions...for Patients
> Message-ID: <000001bfa74c$59a371a0$9018ddcc@olddad66>
> MIME-Version: 1.0
> Content-Type: multipart/mixed;
> boundary="----=_NextPart_000_0066_01BFA720.B4D7D920"
>
> ------=_NextPart_000_0066_01BFA720.B4D7D920
> Content-Type: multipart/alternative;
> boundary="----=_NextPart_001_0067_01BFA720.B4DF7A40"
>
> ------=_NextPart_001_0067_01BFA720.B4DF7A40
> Content-Type: text/plain;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> Again, I have typed this article word-for-word. I also have given you > the option of going to the Genzyme website (at the very end of this > article) to reat this article.
>
> If you were not able to understand "About Adhesions", which was meant > for clinicians, this Genzyme article for patients may help you to have a > better understanding of adhesions and chronic pain. This article may > also help you understand why surgeons are so reluctant to do surgery for > patients, who are known to have developed adhesions in prior surgeries. >
> You will learn that adhesions are " fibrous bands that connect tissue > surfaces that are normally separate." And in this article you will > learn that your chronic pain " is NOT all in your head! ", as you may > have been told. Adhesions do cause chronic pelvic pain!!
>
> *+*+*+*+*+*+*+*+*+*+*+*
>
> [] What are Adhesions?
>
> Adhesion formation is a normal, natural consequence of surgery, > resulting when tissue repairs itself following incision, cauterization, > suturing, or other means of trauma. At the site of such damage, tissues > that normally should remain separate often become "stuck" together by > fibrous scar tissue, called adhesions. This process generally occurs > within the first few days following surgery.
>
> Adhesions can lead to serious complications including small bowel > obstruction, female infertility, chronic debilitating pain and > difficulty with future operations. Following surgery, adhesions may > form, for example, between the incision in the abdominal wall and the > small bowel, preventing the passage of food. This obstruction can lead > to vomiting and debilitating pain. In extreme cases, the bowel may > rupture, necessitating emergency surgery for the patient.
>
> The incidence of adhesions is overwhelming. Adhesions develop in up to > 93 percent of patients following abdominal and pelvic surgery. > Postsurgical adhesions cause up to 74 percent of bowel obstructions. > Over 20 percent of adhesive intestinal obstructions occur within one > month of surgery, and up to 40 percent will occur within one year.
>
> The consequences of adhesions are substantial. Postsurgical adhesions > are responsible for 20-50 percent of chronic pelvic pain cases. > Adhesions also are a leading cause of female fertility, causing 15-20 > percent of cases. Quality of life is greatly impaired.
>
> Quite often a patient will undergo surgery to lyse (remove) adhesions, > only to have them reform. Once a patient has undergone a colorectal > procedure, the incidence of reoperation within two years is high--up to > 20 percent of those patients will have a subsequent colorectal procedure > in that time. Between 2.3 percent and 5 percent of patients will > undergo adhesiolysis for bowel obstruction within two years of > colorectal surgery.
>
> Reoperations are often complicated by adhesions. Consequently, surgeons > must spend a considerable amount of time from ten minutes to hours > dividing adhesions before the current procedure can begin. This > prolongs the patient's recovery and increases the surgical risk and > cost.
>
> http://www.genzyme.com/prodserv/surgical_products/seprafilm/patients/welc> ome.htm
>
> ------=_NextPart_001_0067_01BFA720.B4DF7A40
> Content-Type: text/html;
> charset="iso-8859-1"
> Content-Transfer-Encoding: quoted-printable
>
> <!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
> <HTML><HEAD>
> <META content="text/html; charset=iso-8859-1" > http-equiv=Content-Type>
> <META content="MSHTML 5.00.2919.6307" name=GENERATOR>
> <STYLE></STYLE>
> </HEAD>
> <BODY bgColor=#ffffff>
> <DIV><FONT face=Arial size=2>Again, I have typed this article
> word-for-word. I also have given you the option of going to the > Genzyme
> website (at the very end of this article) to reat this > article.</FONT></DIV>
> <DIV><FONT face=Arial size=2></FONT> </DIV>
> <DIV><FONT face=Arial size=2>If you were not able to understand > "About
> Adhesions", which was meant for clinicians, this Genzyme article for > patients
> may help you to have a better understanding of adhesions and chronic
> pain. This article may also help you understand why surgeons > are so
> reluctant to do surgery for patients, who are known to have developed
> adhesions in prior surgeries. </FONT></DIV>
> <DIV><FONT face=Arial size=2></FONT> </DIV>
> <DIV><FONT face=Arial size=2>You will learn that adhesions are " > fibrous bands
> that connect tissue surfaces that are normally separate." > And in this
> article you will learn that your chronic pain " is NOT all in your head! >
> ", as you may have been told. Adhesions do cause chronic > pelvic
> pain!!</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>*+*+*+*+*+*+*+*+*+*+*+*</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>[] What are > Adhesions?</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Adhesion formation is a normal, natural > consequence
> of surgery, resulting when tissue repairs itself following incision,
> cauterization, suturing, or other means of trauma. At the site of > such
> damage, tissues that normally should remain separate often become > "stuck"
> together by fibrous scar tissue, called adhesions. This process > generally
> occurs within the first few days following surgery.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Adhesions can lead to serious > complications
> including small bowel obstruction, female infertility, chronic > debilitating pain
> and difficulty with future operations. Following surgery, > adhesions may
> form, for example, between the incision in the abdominal wall and the > small
> bowel, preventing the passage of food. This obstruction can lead > to
> vomiting and debilitating pain. In extreme cases, the bowel may > rupture,
> necessitating emergency surgery for the patient.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>The incidence of adhesions is > overwhelming.
> Adhesions develop in up to 93 percent of patients following abdominal > and pelvic
> surgery. Postsurgical adhesions cause up to 74 percent of bowel
> obstructions. Over 20 percent of adhesive intestinal obstructions > occur
> within one month of surgery, and up to 40 percent will occur within one
> year.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>The consequences of adhesions are
> substantial. Postsurgical adhesions are responsible for 20-50 > percent of
> chronic pelvic pain cases. Adhesions also are a leading cause of > female
> fertility, causing 15-20 percent of cases. Quality of life is > greatly
> impaired.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Quite often a patient will undergo > surgery to lyse
> (remove) adhesions, only to have them reform. Once a patient has > undergone
> a colorectal procedure, the incidence of reoperation within two years is >
> high--up to 20 percent of those patients will have a subsequent > colorectal
> procedure in that time. Between 2.3 percent and 5 percent of > patients will
> undergo adhesiolysis for bowel obstruction within two years of > colorectal
> surgery.</FONT></DIV>
> <DIV> </DIV>
> <DIV><FONT face=Arial size=2>Reoperations are often complicated by
> adhesions. Consequently, surgeons must spend a considerable amount > of time
> from ten minutes to hours dividing adhesions before the current > procedure can
> begin. This prolongs the patient's recovery and increases the > surgical
> risk and cost.</FONT></DIV>
> <DIV> </DIV>
> <DIV><A
> href="http://www.genzyme.com/prodserv/surgical_products/seprafilm/patie> nts/welcome.htm">http://www.genzyme.com/prodserv/surgical_products/sepraf> ilm/patients/welcome.htm</A></DIV></BODY></HTML>
>
> ------=_NextPart_001_0067_01BFA720.B4DF7A40--
>
> ------=_NextPart_000_0066_01BFA720.B4D7D920
> Content-Type: application/octet-stream;
> name="Seprafilm® Bioresorbable Membrane Patient Information.url"
> Content-Transfer-Encoding: quoted-printable
> Content-Disposition: attachment;
> filename="Seprafilm® Bioresorbable Membrane Patient Information.url"
>
> [DEFAULT]
> BASEURL=http://www.genzyme.com/prodserv/surgical_products/seprafilm/pat> ients/welcome.htm
>
> [InternetShortcut]
> URL=http://www.genzyme.com/prodserv/surgical_products/seprafilm/patient> s/welcome.htm
> Modified�4289AA44A7BF0120
>
> ------=_NextPart_000_0066_01BFA720.B4D7D920--
>
> ------------------------------
>
> ------------------------------
> End of ADHESIONS Digest 390
> ------------------------------
> ***************************
To remove yourself from the adhesions@adhesions.org mailing list please go
to the unsubscribe form at http://www.adhesions.org/forums/listcmds.htm